← Back to all trials
Active Not Recruiting
NCT07570069
Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants
Conditions: Pain
Sex: All
Ages: 18 Years – 55 Years
Healthy volunteers: Yes
Phase: PHASE1
Enrollment: 18
Sponsor: Vertex Pharmaceuticals Incorporated
Location: ICON - Utah - Salt Lake City Office Salt Lake City Utah
Summary
The purpose of the study is to evaluate the pharmacokinetics (PK) of Suzetrigine (SUZ) and its metabolite in the absence and presence of efavirenz, a moderate CYP3A inducer. In addition, the purpose is to evaluate the safety and tolerability of SUZ when administered in the absence and presence of efavirenz.
Eligibility Criteria
Key Inclusion Criteria:
* Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2)
* A total body weight of greater than (\>) 50 kg
* Males and females of non-childbearing potential
Key Exclusion Criteria:
* History of any illness or any clinical condition that may confound the results of the study or pose an additional risk in administering study drug to the participant
* History of febrile illness or other acute illness that has not fully resolved within 5 days before the first dose of study drug
* Any condition possibly affecting drug absorption
Other protocol defined Inclusion/Exclusion criteria may apply.
Source: ClinicalTrials.gov (NCT07570069). StuddyBuddy aggregates publicly available trial information.
